- Home
- LOAN vs ELUT Comparison
LOAN vs ELUT Comparison
Compare LOAN & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOAN | ELUT |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 48.3M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LOAN | ELUT |
|---|---|---|
| Price | $4.56 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 31.3K | ★ 75.2K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.48% | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | 0.11 | ★ 0.87 |
| Revenue | $8,666,307.00 | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | $42.18 | ★ $1.32 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.13 | $0.50 |
| 52 Week High | $5.85 | $2.60 |
Technical Indicators
Market Signals| Indicator | LOAN | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 50.60 |
| Support Level | $4.33 | $1.00 |
| Resistance Level | $4.90 | $1.16 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 43.75 | 61.11 |
Price Performance
Historical ComparisonAbout LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.